190 related articles for article (PubMed ID: 37958444)
1. Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer.
Schaaf ZA; Ning S; Leslie AR; Sharifi M; Han X; Armstrong C; Lou W; Lombard AP; Liu C; Gao AC
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958444
[TBL] [Abstract][Full Text] [Related]
2. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.
Lombard AP; Liu L; Cucchiara V; Liu C; Armstrong CM; Zhao R; Yang JC; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2018 Oct; 17(10):2197-2205. PubMed ID: 29891490
[TBL] [Abstract][Full Text] [Related]
3. Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer.
Lombard AP; Armstrong CM; D'Abronzo LS; Ning S; Leslie AR; Sharifi M; Lou W; Evans CP; Dall'Era M; Chen HW; Chen X; Gao AC
Mol Cancer Ther; 2022 Apr; 21(4):677-685. PubMed ID: 35086956
[TBL] [Abstract][Full Text] [Related]
4. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
6. Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer.
Cattrini C; España R; Mennitto A; Bersanelli M; Castro E; Olmos D; Lorente D; Gennari A
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572748
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
9. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
10. Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs.
Turco F; Gillessen S; Cathomas R; Buttigliero C; Vogl UM
Res Rep Urol; 2022; 14():339-350. PubMed ID: 36199275
[TBL] [Abstract][Full Text] [Related]
11. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G
Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
[TBL] [Abstract][Full Text] [Related]
12. IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer.
Leslie AR; Ning S; Armstrong CM; D'Abronzo LS; Sharifi M; Schaaf ZA; Lou W; Liu C; Evans CP; Lombard AP; Gao AC
iScience; 2024 Feb; 27(2):108984. PubMed ID: 38327800
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic.
Rahnama'i MS
Am J Mens Health; 2022; 16(4):15579883221115593. PubMed ID: 35950609
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.
Xu P; Yang JC; Chen B; Nip C; Van Dyke JE; Zhang X; Chen HW; Evans CP; Murphy WJ; Liu C
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37147019
[TBL] [Abstract][Full Text] [Related]
16. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
[TBL] [Abstract][Full Text] [Related]
17. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO
Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Zhang X; Zhang G; Wang J; Bi J
Front Endocrinol (Lausanne); 2023; 14():1131033. PubMed ID: 36843606
[TBL] [Abstract][Full Text] [Related]
19. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
20. Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.
Bjartell A; Costa L; Kramer G; Zurawski B; Galli L; Werbrouck P; Ecke T; Parikh O; Bennamoun M; Garcia Freire C; Peer A; Ljungberg B; Cicin I; Smith E; Lukac M; Wapenaar R; Chowdhury S
Eur Urol Open Sci; 2022 Nov; 45():12-22. PubMed ID: 36353661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
